Q2 2026 Kura Oncology, Inc. Earnings Call Transcript
Key Points
- KOMZIFTI generated $9.1 million in net product revenue in Q2 2026, exceeding expectations and capturing a majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market in only its second full commercial quarter.
- Clinical data for ziftomenib in frontline AML (KOMET-007) showed high remission rates and a 94% 12-month overall survival, with no added myelosuppression, supporting its potential as a foundational therapy.
- Darlifarnib demonstrated promising efficacy in renal cell carcinoma and KRAS G12C solid tumors, with objective response rates up to 50% and a manageable safety profile, positioning it as a second strategic asset.
- The company maintains a strong financial position with $519 million in cash and short-term investments, expected to fund the ziftomenib AML program through the first top-line phase III results in 2028.
- KOMZIFTI has achieved over 95% covered lives and 16 million lives with preferred status, with no prior authorization challenges, facilitating physician adoption and repeat prescribing.
- Kura Oncology Inc (KURA) reported a net loss of $68.3 million in Q2 2026, with SG&A expenses increasing to $31.8 million from $25.2 million year-over-year, reflecting higher commercial costs.
- The company faces competitive pressure from Syndax, with both companies claiming majority share of new patient starts, creating market share ambiguity and potential investor confusion.
- KOMZIFTI's revenue is still relatively small at $9.1 million, and the launch is in early stages, with duration of therapy and long-term outcomes yet to be established.
- The darlifarnib program is in early development, with the randomized phase 1b portion of FIT-001 not expected to complete enrollment until the first half of 2027, and initial data not until the second half of the year.
- The company's cash position decreased from $667.2 million at the end of 2025 to $519 million as of June 30, 2026, and the company is not yet profitable, relying on future milestones and collaboration payments to fund operations.
My name is Lenius, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology second quarter 2026 financial results earnings call. (Operator Instructions)
At this time, I would like to turn the call over to Greg Mann, Senior Vice President of Investor Relations and Corporate Affairs of Kura Oncology. Please go ahead.
Thank you, Lenius. Good afternoon, and welcome to Kura Oncology second quarter 2026 conference call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer, Brian Powl, Chief Commercial Officer, Dr. Mollie Leoni, Chief Medical Officer, and Tom Doyle, Senior Vice President, Finance and Accounting.
We remind you that today's discussion will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
